Newsquawk Logo

Merck & Co. (MRK) Q4 2025 (USD): adj. EPS 2.04 (exp. 2.01), Revenue 16.4bln (exp. 16.20bln)

Merck & Co.

Newsquawk StaffPublished On the live feed at — 5 more headlines followed before this page went public
Newsquawk headlinesUTC

Pfizer (PFE) reported ultra-long-acting injectable GLP-1 RA shows robust and continued weight loss with monthly dosing in Phase 2b trial

China's Premier Li to meet with Logitech's (LOGN SW) CEO

Merck & Co. (MRK) Q4 2025 (USD): adj. EPS 2.04 (exp. 2.01), Revenue 16.4bln (exp. 16.20bln)

UKMTO has received a report of an incident 16NM north of Oman within the inbound TSS of the Straits of Hormuz

China's Shanghai Futures Exchange to adjust price limits, margin requirements for fuel oil and other futures contracts from the 5th of February closing settlements

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.

KEY PHARMA SALES:

  • Q4 Keytruda Sales USD 8.37bln (exp. 8.31bln)
  • Q4 Gardasil Sales USD 1.03bln (exp. 0.991bln)
  • Q4 Winrevair Sales USD 467mln 

GUIDANCE:

  • FY EPS view 5.00-5.15 (exp. 5.27)
  • FY Rev. view USD 65.5-67.0bln (exp. 67.4bln)
Context

reported a strong Q4 2025 with adjusted EPS and revenue exceeding expectations, particularly boosted by solid Keytruda and Gardasil sales. However, the guidance for FY EPS and revenue was below consensus, which may raise concerns about future growth prospects. The mixed signals suggest the market will focus on the strength of current sales against the potential for lower future performance.

External

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.